The four members of the EGF receptor family are capable of homomeric as well as heteromeric interactions. HER-2/neu (erbB-2) dominates as the preferred coreceptor that ampli®es mitogenic signaling. An alternative HER-2/neu product, herstatin, consists of a segment of the ectodomain of p185HER-2 and an intronencoded C-terminus. Recombinant herstatin was found to bind with nM anity and inhibit p185HER-2. To further examine the impact on receptor activity, herstatin was expressed with various receptor tyrosine kinases. In CHO cells that overexpressed HER-2, herstatin caused a sevenfold inhibition of colony formation that corresponded to a reduction in the tyrosine phosphorylation of p185HER-2. Herstatin also prevented HER-2 mediated transactivation of the kinase impaired HER-3 as re¯ected in transphosphorylation of HER-3 and heteromers between HER-2 and HER-3. In EGF receptor-overexpressing cells, EGF induction of receptor dimerization and tyrosine phosphorylation were reduced more than 90%, and receptor down-regulation as well as colony formation were also suppressed by coexpression with herstatin. Inhibition was selective for the EGF receptor family since herstatin expression did not reduce tyrosine phosphorylation mediated by the FGF receptor-2 or by insulin-like growth factor -1. Herstatin bound to the EGF receptor as well as to p185HER-2 in pull-down assays suggesting that complex formation may be involved in receptor inhibition. Our ®ndings indicate that herstatin has the capability to negatively regulate combinations of interactions between group I receptor tyrosine kinases that confer synergistic growth signals. Oncogene (2001) 20, 5199 ± 5209.
Introduction
The group I receptor tyrosine kinases including the EGF-receptor (HER-1, erbB-1), HER-2 (erbB-2), HER-3 (erbB-3) and HER-4 (erbB-4) are widely expressed in epithelial, mesenchymal and neuronal tissues and play fundamental roles in proliferation and dierentiation Hynes and Stern, 1994; Klapper et al., 2000; Olayioye et al., 2000) . With the exception of HER-2, the group I receptor tyrosine kinases (RTKs) are activated by binding of speci®c EGF-related growth factors. Ligand binding is coupled to receptor dimerization and tyrosine autophosphorylation, which are obligatory steps in signal activation (Heldin and Ostman, 1996) . Independent of speci®c growth factor binding, HER-2 is constitutively active as a homodimer (Di Fiore et al., 1987; Hudziak et al., 1987; Lonardo et al., 1990) , or is recruited as the preferred heterodimer partner where it transactivates group I receptor family members (GrausPorta et al., 1997; Tzahar et al., 1996) .
The major involvement of group I RTKs in survival and proliferation of epithelial cells places these receptors as central targets in cancer research. HER-2 dominates as an ampli®er of growth factor signaling and by its high incidence of overexpression in adenocarcinomas Hynes and Stern, 1994; Klapper et al., 2000) . HER-2 is overexpressed in breast, ovarian, gastric, and endometrial carcinomas. Elevated levels of HER-2 in 25 ± 30% of breast and ovarian cancers predict signi®cantly lower survival rates and shorter time to relapse (Slamon and Clark, 1988; Slamon et al., 1987) . Recent evidence indicates that cooperative interactions between HER-2 and HER-3 synergistically augment signaling pathways in breast cancer cells (Alimandi et al., 1995; Ram et al., 2000; Siegel et al., 1999) . Several epithelial tumors also exhibit EGF receptor (HER-1) overexpression and/or gene rearrangements (Aaronson, 1991) . Overexpression is often associated with increased production of EGF-like growth factors, which activate endogenous receptors via an autocrine mechanism (Baselga and Mendelsohn, 1997) .
The group I receptor extracellular domains are critical for understanding receptor activation and are important targets for blocking receptor action at the cell surface. The ectodomains, in the absence of the cytoplasmic domains, are capable of self dimerization and codimerization with full-length receptors (Lemmon et al., 1997; Qian et al., 1996; Tanner and Kyte, 1999; Tzahar et al., 1997) . Beginning at the N-terminus, the ectodomains have been divided into subdomains I through IV (Lax et al., 1988) . Subdomains II and IV contain multiple cysteine residues that are conserved among the four group I receptors. Subdomains I and II appear to be a repeating unit of III and IV that may have arose by a gene duplication event (Ullrich et al., 1984) . Subdomain III contains the high anity ligand binding site (Lax et al., 1989 (Lax et al., , 1991 Woltjer et al., 1992) , and subdomain I may serve as a low anity, promiscuous ligand binding site (Lax et al., 1989 (Lax et al., , 1991 Tzahar et al., 1997) . Dimerization can be achieved in the absence of subdomains I and II, since their deletion from the EGF receptor results in constitutive dimerization and oncogenic transformation in a ligandindependent fashion (Carter and Kung, 1994; Moscatello et al., 1996; Qian et al., 1994) . Moreover, ligand independent heterodimers can be formed between EGF receptors missing subdomains I and II and the membrane anchored p185neu ectodomain mutant (O'Rourke et al., 1997) . These ®ndings suggest that subdomains I and II are not absolutely required for dimer formation and may prevent oligomerization in the absence of ligand.
Monoclonal antibodies against the ectodomains of p185HER-2 and the EGF-receptor are eective in limiting growth of tumor cells (Fendly et al., 1990; Katsumata et al., 1995; Klapper et al., 2000; . Systemic administration of rhuMAb4D5 has been shown to increase the time to recurrence in a subset of patients with metastatic breast cancer (Baselga et al., 1996; Cobleigh et al., 1999; Pegram et al., 1998) . The rhuMAb4D5 antibody may act by downregulation of p185HER-2 at the cell surface (Hurwitz et al., 1995) . While the molecular mechanisms underlying the activity of EGF receptor antibodies are not clearly established, they often compete with growth factor binding . Antibody combinations that target both p185HER-2 and the EGFreceptor have also been employed. Preliminary evidence suggests that targeting both receptors may signi®cantly augment antitumor eects (Ye et al., 1999) .
Another strategy uses mutant receptors consisting of ectodomains and a membrane anchor in the absence of the cytoplasmic domain. The truncation mutants function as dominant negative inhibitors based on their ability to dimerize with group I receptors, forming kinase inactive complexes (Chou et al., 1987; Kashles et al., 1991) . Expression of the membraneanchored ectodomain of p185 neu inhibits p185HER-2 homodimer signaling as well as trans-inhibits EGF receptor signaling (Qian et al., , 1996 . Since p185HER-2 is the preferred heterodimer partner of group I RTKs (Graus-Porta et al., 1997; Tzahar et al., 1996) , then the p185 ectodomain has the potential to suppress the activation of all group I receptors, suggesting therapeutic value against advanced human cancers. However, interactions between soluble ectodomains and cell surface receptors are weak (mM anity) requiring membrane anchoring to exert a dominant negative eect (O'Rourke et al., 1997; Tzahar et al., 1997) .
Recently, we discovered a naturally occurring inhibitor of the HER-2 receptor tyrosine kinase called herstatin, which is generated by retention of intron 8 in HER-2 alternative mRNA. Herstatin consists of the ®rst 340 aa-residues identical to N-terminal subdomains I and II of p185HER-2, followed by a novel Cterminus of 79 aa-residues and a stop codon speci®ed by the inserted sequence. Herstatin binds with high anity (K d *14 nM) to cell surface p185HER-2 (Doherty et al., 1999) . In the current study we address the consequences of ectopic expression of herstatin to the activity of HER-2, HER-3 and the EGF receptor. These results show that ectopic expression of herstatin not only interrupts constitutive activation of HER-2, but also interferes with growth factor induction of HER-2/HER-3 heterodimers and with EGF activation of the EGF receptor. The ability of herstatin to suppress colony formation of p185HER-2 or EGF receptor-overexpressing cells suggests its potential use in limiting tumor cell growth that is driven by these receptors.
Results
To analyse the eects of ectopic expression of herstatin on receptor activity, herstatin and HER-2 expression plasmids were transfected into CHO cells. Western blot analysis and imaging densitometry revealed that p185HER-2 levels in the cultures appeared to be reduced about threefold by coexpression with herstatin ( Figure 1a ). While p185HER-2 was reduced, herstatin, expressed as a protein of about 60 kDa, was elevated about 10-fold in the cells cotransfected with HER-2 and herstatin ( Figure 1a) . To examine whether expression of herstatin and/or p185HER-2 may have aected the viability of the transfected cells, a b-galactosidase reporter plasmid was included in the transfections, since the same population of cells in a culture can be expected to take up the dierent plasmids (Weintraub et al., 1986) . Expression of the reporter plasmid was slightly enhanced in extracts from the HER-2 transfected cultures relative to the control culture (Figure 1b) . In contrast, transfection with herstatin reduced expression of the reporter plasmid by about fourfold ( Figure  1b) . Introduction of HER-2 with herstatin resulted in an increase in b-gal activity (about 2.5-fold) over cells transfected with herstatin alone, while the b-gal activity was repressed about threefold in the cotransfected cells relative to cells that expressed HER-2 alone. These data suggest that the viability of transfected cells, measured by b-gal activity, was reduced by herstatin expression, while overexpression of HER-2 appeared to enhance survival. Notably, the b-gal activity was nearly sevenfold lower in cells that expressed herstatin compared to cells that overexpressed HER-2. To more accurately appraise the expression of herstatin and p185HER-2 in the transfected cells, the relative amounts of these proteins, indicated by densitometric scanning of Western blots, were normalized to b-gal activity (Figure 1c) . Herstatin normalized to b-gal activity was elevated about fourfold when HER-2 was coexpressed. This increase was consistently observed in several cell lines including CHO, Cos-7 and HEK-293 cells (data not shown). p185HER-2 levels normalized to b-gal activity were similar in cells transfected with or without herstatin suggesting that herstatin does not aect production of p185HER-2. Moreover, the electrophoretic mobility of p185HER-2 was not altered by herstatin expression (Figure 1a) , suggesting that receptor processing was normal. Previous studies have demonstrated that p185HER-2, retained in the endoplasmic reticulum, has an increased electrophoretic mobility suggestive of underglycosylation Graus-Porta et al., 1995) . Taken together these ®ndings are consistent with the hypothesis that herstatin expression diminishes survival, but does not alter the production of p185HER-2, while expression of p185HER-2 stimulates the expression of herstatin in the transiently transfected cells.
Herstatin expression inhibits the tyrosine phosphorylation of p185HER-2
The impact of herstatin was further evaluated by transfecting cells with varying amounts of herstatin expression plasmid in the presence of constant amounts of HER-2 plasmid. Herstatin reduced both the levels of p185HER-2 in the extracts and the expression of a reporter plasmid in agreement with results shown in Figure 1b . As the amount of herstatin plasmid was increased, there was a striking reduction in the p185 tyrosine phosphorylation signal (Figure 2b , lanes 3 ± 6). Quantitation of the signals generated with the antiphosphotyrosine antibody ( Figure 2b ) and with the 5 per well into six well plates and transfected with 1.5 mg of herstatin (lane 1), 1.5 mg of herstatin plus 1.5 mg of HER-2 (lane 2), or with 1.5 mg of HER-2 (lane 3) expression plasmids (in the pcDNA3.1 vector from Invitrogen) using Lipofectamine (Gibco ± BRL). The total amount of DNA added to each well was adjusted to 3 mg using control DNA (pcDNA3.1 empty vector). In (a) the transfected cells were analysed at 48 h as a Western blot and the blots were developed using chemiluminescent reagent (Pierce) and exposed to Kodak ®lm. The ®lms were scanned by imaging densitometry (BioRad, model GS700) to assess relative levels. Dierent exposures of the ®lm were compared to ensure linear densitometry. In the upper panel the blot was reacted with antibodies against p185HER-2, anti-neu(C). In the lower panel, transfected cells were analyzed as a Western with antibodies against the intron 8-encoded sequence, which is speci®c to herstatin (anti-Hst). In (b) the transfections were conducted in triplicate wells using the indicated plasmids with the inclusion of 0.5 mg of b-galactosidase expression plasmid driven by a CMV promoter. At 48 h, the cells were extracted, cell protein was quantitated by BioRad protein dye kit, and the b-gal activity was measured as described (Sambrook et al., 1989 ) and normalized to cell protein. The mean and standard deviation of triplicate wells are shown in the plot. In (c) the graph on the left illustrates the p185HER-2 signal (from panel a) divided by the mean b-gal activity (from panel b) normalized to the value obtained for cells transfected with HER-2 alone. In the graph on the right, the herstatin signal divided by mean b-gal activity is normalized to the value obtained for cells transfected with herstatin alone. Similar results were obtained in at least four separate experiments HER 2-speci®c antibody ( Figure 2a ) in lanes 2 ± 6 revealed a herstatin-dependent decrease in the tyrosine phosphorylation of p185HER-2 with a 25-fold reduction when the ratio of herstatin to HER-2 was 2 : 1 ( Figure 2c ). The inhibition in tyrosine phosphorylation was also observed in Cos-7 cells and in HEK-293 cells cotransfected with HER-2 and herstatin (data not shown). Endogenous p185HER-2 was detected in the control and herstatin transfected cells with longer exposure of the immunoblot in Figure 2a (lanes 1 and 2). The phosphotyrosine signal associated with endogenous p185 was reduced by about twofold with the introduction of herstatin (compare lanes 1 and 2 Figure 2b ).
Herstatin inhibits clonal growth of transfected CHO cells
To determine the eects of herstatin on cell behavior, the colony forming ability of the transfected cells was measured. CHO cells were transfected, subjected to selection with G418 for 20 days, and the surviving cell colonies were quantitated by the MTT live cell assay or were stained with crystal violet. The clonogenic assay measures the capacity of cells to establish and form colonies and re¯ects cell survival as well as proliferation. Transfection with HER-2 enhanced colony formation by about 60% compared to the control transfected cells (Figure 3a) , consistent with studies showing that overexpression of HER-2 confers a growth and survival advantage to a number of cell types (Chazin et al., 1992; Hudziak et al., 1988) . Introduction of herstatin, however, reduced colonization ( Figure 3a) . The most dramatic eect was observed when herstatin was combined with HER-2. Compared to cells that overexpressed p185HER-2, colony formation was reduced about sevenfold in the cotransfected cells (Figure 3a,b) . It was possible that G418 resistant colonies may not coordinately express the cotransfected plasmids. We therefore analysed 10 colonies and found that they each expressed p185HER-2, but little herstatin was detected (data not shown). This indicated that the cells that expressed herstatin did not survive. Therefore, the extent of colony inhibition by herstatin may be underestimated.
Herstatin blocks heregulin-dependent transactivation of HER-3 by HER-2
Interference with HER-2 dimers by herstatin (Doherty et al., 1999) raised the possibility that it may also prevent the heteromeric interaction of HER-2 with other group I RTKs. The growth factor heregulin (neu dierentiation factor) (Holmes et al., 1992; Peles et al., 1992) directly binds to HER-3 causing recruitment of other group I receptors, with HER-2 as the preferred heterodimer partner (Graus-Porta et al., 1997; Tzahar et al., 1996) . In CHO cells, herstatin transfected with HER-2 and HER-3 prevented heregulin-induced tyrosine phosphorylation of proteins of *185 kDa, which is the approximate size of both RTKs (data not shown). However expression levels of the transfected receptors were higher in the Cos-7 cells facilitating the detection of immunoprecipitated proteins, particularly with the weaker anti-HER-3 antibody. Therefore, Cos-7 cells were transfected with HER-2 and HER-3 in the presence or absence of herstatin, and then were treated with vehicle or with 2 nM heregulin for 20 min. The T691 mutant was also introduced with HER-2 and HER-3, since it behaves as a dominant negative inhibitor of HER-2 heteromeric interactions (O'Rourke et al., 1997; Qian et al., 1994) . Heregulin induced the tyrosine phosphorylation of HER-3 in the cells transfected with both RTKs (Figure 4a ). Given that HER-3 possesses impaired tyrosine kinase activity and depends on other group I receptors to become phosphorylated (Guy et al., 1994 ; Pinkas-Kramarski Figure 2 Herstatin expression inhibits p185HER-2 tyrosine phosphorylation. In (a) and (b) CHO cells were transfected with 3 mg of control empty vector (lane 1), 1.5 mg herstatin plasmid (lane 2), 1.5 mg HER-2 plasmid (lanes 3 ± 6), and 0, 0.5, 1.5 and 3 mg herstatin plasmid (lanes 3 ± 6 respectively). The total amount of DNA in each well was adjusted to 3 mg using empty vector. In (b) 20 mg of the extract protein were analysed as a Western blot ®rst using 4G10 anti-phosphotyrosine antibody (anti-PTyr). The membrane blot was stripped by incubation at 508C for 30 min with shaking in 0.625 M Tris pH 6.5, 100 mM dithiothreitol and 2% SDS, and then was blocked with 5% nonfat dry milk. The membrane was examined to ensure complete stripping by applying chemiluminescent reagent and exposing to ®lm for 5 min. A duplicate blot was also probed directly with anti-neu(C) to rule out possible stripping artifacts. In (a), the stipped blot was reacted with antibodies against p185HER-2 (anti-neu(C). In (c), dierent exposures of the ®lms shown in a and b were scanned by imaging densitometry and the signal from cells transfected with HER-2 in the absence of herstatin (lane 3) was set at 100% et al., 1996), it is likely that the HER-3 tyrosine phosphorylation resulted from transmodulation by HER-2. In support of this, induction of HER-3 tyrosine phosphorylation required ectopic expression of HER-2 (data not shown). Introduction of herstatin as well as T691 dramatically decreased the tyrosine phosphorylation of HER-3 (Figure 4a,b) . Herstatin expression also diminished the association of HER-2 with HER-3 in the heregulin treated cells (Figure 4c ). These ®ndings show that herstatin blocks the ability of HER-2 to associate with and transactivate HER-3 in response to exogenous heregulin.
Herstatin inhibits EGF activation of the EGF-receptor
To examine whether the inhibitory activity might extend to other group I RTKs, we next examined the impact of herstatin on the EGF receptor. CHO cells were transfected with the control empty vector, with the EGF-receptor, or with the EGF receptor combined with herstatin. EGF receptors could not be detected in the control transfected cells (Figure 5d , lane 1), consistent with previous reports that CHO cells lack group I receptors other than HER-2 . Addition of EGF to the serum starved cells resulted in activation of the EGF receptor as demonstrated by enhanced receptor dimerization and tyrosine phosphorylation (Figure 5a,b,c, lanes 1 and 2,  panels a,b,c) . Coexpression of herstatin with the EGF receptor greatly reduced the ability of EGF to induce dimerization ( Figure 5c ) and tyrosine phosphorylation of the receptor (Figure 5a,b, lanes 3 and 4) . EGF has also been shown to induce down regulation of the Triplicate wells of CHO cells were transfected with 3 mg of control empty plasmid pcDNA3.1; with 1.5 mg of HER-2; with 1.5 mg of HER-2 plus 1.5 mg of herstatin; or with 1.5 mg of herstatin. The amount of DNA in each well was adjusted to 3 mg with the bacterial pET 15 (Novagen) empty vector since the empty pcDNA3.1 vector confers G418 resistance. At 48 h after addition of DNA, the cells were treated with 0.6 mg/ml of G418. The media was changed every 2 days. At 14 days, live cells were quantitated using the MTT assay (Hansen et al., 1989) . The mean and standard deviation of triplicate wells are plotted in (a). In (b) cultures were stained with crystal violet Figure 4 Herstatin expression blocks transactivation of HER-3. CHO cells (10 6 ) were plated in 10 cm plates and transfected with 2 mg of HER-3 plus 2 mg of HER-2, and either 2 mg of herstatin or 2 mg control plasmid. At 24 h, the cultures were changed to serum-free media for 24 h and then 2 nM heregulin or vehicle were added for 20 min. The cultures were extracted, protein amounts were determined and 20 mg were analysed directly as a Western blot in b and d, or 1 mg of protein from each was immunoprecipitated as described in the Materials and methods section. In (a) samples were immunoprecipitated with 5 mg of antiphosphotyrosine antibody and then analysed as a Western blot with anti-HER-3 antibody. In (c) samples were immunoprecipitated with 5 ml of anti HER-3 antibody and then analysed as a Western blot with anti neu-C antibody activated EGF receptor (Sorkin and Waters, 1993) . Figure 5d demonstrates that treatment with EGF for 48 h reduced the level of the receptor suggesting down regulation (lanes 2 and 3), while introduction of herstatin prevented this EGF-dependent eect (lanes 4 and 5). The inhibition of EGF receptor activation occurred at saturating concentrations of EGF (100 ng/ ml) and the extent of inhibition was not noticeably altered as the concentration was further increased to 300 ng/ml. To investigate the eects on colony formation, CHO cells were transfected with the EGF receptor in the presence and absence of herstatin and selected with G418 as in Figure 2 . When the EGF receptor alone was overexpressed, there was an increase in clonal formation relative to the control transfected cells (Figure 5e ). In comparison, introduction of herstatin reduced colony formation by about 45% (Figure 5e) . These combined results demonstrate that herstatin prevents activation of the EGF receptor by exogenous EGF and suggests an inhibitory eect on Figure 5 Herstatin expression inhibits EGF activation of the EGF receptor. CHO cells in six well plates were transfected with 1.5 mg of empty vector, with 1.5 mg of EGF receptor, or with 1.5 mg of EGF receptor plus 0.5 mg of herstatin expression plasmid. The total amount of DNA added to each well was equalized using empty vector DNA. At 24 h the cells were washed twice with PBS and cultured in serum free media for 24 h and then incubated at 378C with 100 ng/ml EGF or vehicle for 30 min. Twenty mg of protein from each well were resolved in 7.5% polyacrylamide SDS-gels and analysed as a Western blot with anti-phosphotyrosine antibody (b), or with anti-EGF receptor antibody (a). In (c) CHO cells (2610 6 cells in 10 cm culture dishes) were transfected with 2 mg of EGF receptor expression plasmid in the presence or absence of 2 mg of herstatin expression plasmid and treated with or without 100 ng/ml of EGF for 30 min at 378C. The cells were then incubated with 1 mM BS3 (Pierce) cross-linking reagent for 30 min at room temperature and then immunoprecipitated with antibodies speci®c for the EGF receptor. The immune complexes were then analysed as a Western blot using 5% SDS-polyacrylamide gels and reacting with anti-EGF receptor antibody. No EGF receptor dimers were detected in the absence of cross-linking reagent (data not shown). In (d) the transfected cells were incubated in serum-free media for 24 h treated or not with EGF for 48 h and then analysed as a Western blot with anti-EGF receptor antibodies. In (e) The transfected cell cultures in six well plates were selected with G418 and colony formation was analysed as described in Figure 3 . The mean value of triplicate wells, determined as the per cent of the control transfected cells are plotted with the standard deviations. A similar result was obtained in three separate experiments the survival/and or growth of CHO cells that overexpress the EGF receptor.
Herstatin effects are specific for the EGF receptor family
To address receptor speci®city, the eects of herstatin were tested on the FGF receptor-2, a group III RTK with immunoglobulin-like domains in its extracellular region. Like other RTKs, the FGF receptor-2 is activated by dimerization and is tyrosine phosphorylated by an intermolecular transphosphorylation mechanism (Fantl et al., 1993) . The *119 kDa receptor (Figure 6a , upper panel) with a high level of constitutive tyrosine phosphorylation (Figure 6a , lower panel) was detected in CHO cells transfected with the FGF receptor-2 expression plasmid. The extent of phosphorylation, however, was not signi®cantly altered by herstatin expression. Speci®city was further assessed by treating herstatin or control transfected cells with EGF or with insulin-like growth factor-1 (IGF-1) and examining signaling by the endogenous receptors. The IGF-1 receptor is a member of an RTK family distinguished by their heterotetrameric structure (Fantl et al., 1993) . While EGF-dependent tyrosine phosphorylation was inhibited, there was no eect on the IGF 1-dependent tyrosine phosphorylation (Figure 6b) . Moreover, in cells treated simultaneously with EGF and IGF-1, tyrosine phosphorylation of the endogenous EGF receptor was inhibited while the IGF-1 receptor, b-subunit, was unaected (Figure 6c ).
Herstatin forms a stable complex with p185HER-2 and the EGF receptor
Both full-length herstatin and its intron 8-encoded Cterminal domain, expressed as recombinant peptides, were previously found to bind to p185HER-2 with nM anity. The ability of herstatin to interfere with EGF activation of the EGF receptor raised the possibility that herstatin may associate with the EGF receptor as well as p185HER-2. The interaction with the EGF receptor was examined using puri®ed intron 8 encoded peptide identical to the C-terminus of herstatin, or the full length recombinant herstatin protein immobilized on protein S agarose. A peptide with irrelevant sequence was also immobilized as a control. The agarose was then incubated with extracts of A431 cells, washed, and analysed as a Western blot with antibodies speci®c for the EGF receptor. Figure 7 demonstrates speci®c association of the EGF receptor with intron 8-encoded peptide and with herstatin, but not with the protein S agarose with or without the irrelevant peptide. It was possible that the EGFR interacted with herstatin because it was in a complex with p185HER-2. While this cannot be completely ruled out, analysis of the protein pulled-down from the A431 cells with antibodies against p185HER-2 failed to detect this protein. For comparison, extracts of 17-3-1 cells, which are stably transfected with p185HER-2, were also examined in the pull-down assay. As previously seen (Doherty et al., 1999) , p185HER-2 associated with intron 8-encoded peptide and herstatin, but not with an irrelevant peptide. We were unable to detect pull-down of HER-3 from MCF-7 cell extracts using either immobilized herstatin or intron 8-encoded peptide (data not shown).
Discussion
HER-2 dominates as the preferred heterodimer partner (Graus-Porta et al., 1997; Tzahar et al., 1996) that ampli®es signaling when combined with all other group I RTKs Karunagaran et al., 1996; Pinkas-Kramarski et al., 1998) . Consequently biological responses such as proliferation, dierentiation and migration/invasion are enhanced in cells that express HER-2 (Di Fiore et al., 1987; PinkasKramarski et al., 1998; Riese and Stern, 1998; Spencer et al., 2000; Tzahar et al., 1996) . Since HER-2 is activated in the absence of a direct acting ligand (Di Fiore et al., 1987; Hudziak et al., 1987; Lonardo et al., 1990) , and is expressed in a variety of tissues, a naturally occurring mechanism to disable HER-2 would seem to be essential. Our ®ndings suggest that herstatin, an alternative product of the HER-2 gene itself, functions to check the signaling activity of HER-2. Here we provide evidence that herstatin expression can abrogate the constitutive activity of p185HER-2 and uncouple its interaction with other group I receptors. Further we demonstrate that herstatin expression can block activation of receptor combinations by exogenous growth factors. The inhibitory activity of herstatin displays selectivity for group I receptors, since FGF receptor-2 activity as well as IGF-1 induction of tyrosine phosphorylation were not aected by expression of herstatin. Since herstatin is expressed in fetal kidney and liver (Doherty et al., 1999) , it may play a role in tissue-speci®c neutralization of group I receptor activity.
Tyrosine phosphorylation of p185HER-2 was inhibited by expression of herstatin. The extent of inhibition depended on the ratio of herstatin to HER-2 introduced into the cells, displaying characteristics typical of dominant negative inhibition. This result is consistent with previous studies showing that puri®ed, recombinant herstatin added to HER-2 transfected 3T3 cells inhibits p185HER-2 tyrosine phosphorylation in a dose-dependent fashion (Doherty et al., 1999 ). In the current study, it is unclear whether intracellular herstatin and/or secreted herstatin were responsible for receptor inhibition. The strong binding of herstatin to p185HER-2 (Doherty et al., 1999; and this study) suggests that complex formation may be the mechanism underlying receptor inhibition.
Of the possible receptor combinations, HER-2 and HER-3 transmit the most potent mitogenic signal, which in turn contributes to uncontrolled tumor cell growth (Alimandi et al., 1995; Kraus et al., 1987; Siegel et al., 1999) . Inhibitors of HER-2/HER-3 heteromeric interactions and their mitogenic signaling are therefore of potential importance as anti-tumor agents. The monoclonal antibody, 2C4, has been found to interfere with heregulin-dependent HER2/HER-3 interactions by binding to p185HER-2 (Fitzpatrick et al., 1998) . Presumably 2C4 blocks or alters a site on the p185HER-2 ectodomain that is required to form high anity heregulin binding sites. The heteromeric interaction between HER-2 and HER-3 can also be prevented by expression of a HER-3 ectodomain mutant anchored to the membrane (Ram et al., 2000) . We now show that herstatin expression can also prevent recruitment of HER-2 into heteromers with HER-3 and, like the T691 ectodomain mutant, can inhibit transphosphorylation of HER-3. While we we have been unable to detect association of HER-3 with herstatin in pull-down assays, studies of herstatin interactions with puri®ed receptor ectodomains may be required to accurately de®ne binding strengths and speci®city. Although the mechanism is not yet established, the interference with HER-2/HER-3 heteromer formation by herstatin may be caused by disabling HER-2. If this model is correct, then herstatin may also prevent HER-2 transactivation of HER-4 and the EGF receptor assuming that the interactions between HER-2 and heteromeric partners are equivalent in the dierent receptor combinations.
Ectopic expression of herstatin also interfered with EGF-activation of the EGF receptor as re¯ected by receptor dimerization, tyrosine phosphorylation, and receptor down regulation. The inhibition was not diminished by excess EGF (100 or 300 ng/ml) suggest- Figure 7 Immobilized intron 8-encoded peptide or herstatin complexes with the EGF receptor and with p185HER-2. One hundred ml of a 50% suspension of S-protein agarose (Novagen) was incubated without peptide or with 50 mg of TBpex 14 peptide (provided by Dr B Ullman, OHSU), 50 mg of intron 8-encoded peptide, or 50 mg full length recombinant herstatin at room temperature for 1 h. Each of these peptides contained an S-protein tag encoded by the pET 30 expression plasmid (Novagen). The agarose samples were then washed twice with PBS and incubated at room temperature for 1 h with 100 mg of protein from cells solubilized in PBS containing 1% nonidet-P40. A431 cells were used to test for complex formation with the EGF receptor and 17-3-1 cells for p185HER-2. After incubation with the cell extracts, the agarose samples were washed twice with 500 ml of PBS-NP40 and the proteins associated with the resin were eluted at 928C for 2 min in 40 ml of SDS-sample buer. To ensure that equal amounts of the peptides were complexed to the agarose, an aliquot, extracted in SDS-sample buer, was analysed by SDS ± PAGE and Coomassie staining of a 17% polyacrylamide gel for TBpex14 and intron 8-encoded peptide, and a 10% polyacrylamide gel for p50 herstatin. To analyse receptor binding, an aliquot eluted from the agarose was analysed as a Western blot using anti-EGFR or anti-p185HER-2 ing that EGF cannot overcome the inhibitory eect. The ability of herstatin to associate with the EGF receptor in pull-down assays (Figure 7) suggests that complex formation could occur either during their biosynthesis and/or through binding of secreted herstatin. It is also possible that herstatin aects the EGF receptor indirectly by preventing EGF-induced heterodimer formation between endogenous p185HER-2 and the exogenous EGF receptor. However, the inhibition of dimers and receptor tyrosine phosphorylation was greater than 90% in the EGF receptor overexpressing cells. This degree of inhibition would not be expected unless EGF receptor homodimers were blocked by herstatin, since endogenous p185HER-2 is at low levels in these cells. Testing of herstatin eects on group I RTKs expressed in a receptor-negative background (Riese et al., 1995) will be necessary, however, to ascertain which receptors are directly aected.
The ability of herstatin to disrupt receptor interactions, which are required for the execution of proliferative signals, suggests involvement in regulation of cell growth. In agreement with this, expression of herstatin in CHO cells reduced the colony forming ability of transfected cells. Since the CHO cells express endogenous p185HER-2 but not other group I receptors, growth inhibition may have been through interaction with the endogenous HER-2. This possibility was further suggested by the diminished tyrosine phosphorylation signal associated with endogenous p185 (Figure 2 ). Herstatin coexpressed with the EGF receptor also suppressed colony formation in CHO cells relative to cells transfected with the EGF receptor alone suggesting the capability of inhibiting the growth and/or survival of cells that overexpress the EGF receptor. It is also possible that suppression of the endogenous p185HER-2 in CHO cells by herstatin may have been the mechanism underlying the growth inhibition Herstatin has several similarities with the previously characterized p185neu ectodomain mutant, T691stop, which also functions as a dominant negative inhibitor. Like herstatin (Doherty et al., 1999 ) the neu mutant contains sequences from the receptor extracellular domain and forms complexes with RTKs (O'Rourke et al., 1997; Qian et al., 1994 Qian et al., , 1996 . Also, both p185 neu ectodomain and herstatin, ectopically expressed, are capable of inhibition of both p185HER-2 and the EGF receptor, as well as heteromeric interactions that include HER-2. In contrast to the neu ectodomain, which consists of subdomains I through IV and a membrane anchor, herstatin is secreted and contains only subdomains I and II along with the intron 8-encoded C-terminus. The high anity binding of herstatin to p185HER-2 (Doherty et al., 1999) probably explains its ability to inhibit receptors in the absence of a membrane anchor. While the intron 8 domain displays high anity binding, studies from our lab indicate that the presence of subdomains I and II are required for dimer inhibition (Doherty et al., 1999, Doherty et al., unpublished observations) . Together these ®ndings indicate that HER-2 subdomains I and II, in the absence of III and IV , are capable of disrupting homodimers of HER-2 and the EGF receptor as well as HER-2/HER-3 heteromeric interactions.
In summary, herstatin displays the ability to disarm HER-2 and to prevent activation of the EGF receptor by exogenous EGF. Therefore, herstatin has the potential to prevent multiple combinations of group I receptor interactions. This inhibitory activity suggests its importance in the normal regulation of group I receptors and in the design of potential cancer therapeutics.
Materials and methods

Plasmids
The human HER-3 expression plasmid was provided by Dr Tracy Ram, Washington State University in Pullman. The mouse FGF-receptor-2 expression plasmid was provided by Dr Felix Eckenstein of OHSU. The human HER-2 plasmid, which speci®es the expression of p185HER-2 was obtained from Dr Adam Geballe Fred Hutchinson Cancer Center, (Seattle, WA, USA). The rat neu ectodomain mutant, T691stop (O'Rourke et al., 1997; Qian et al., 1994 Qian et al., , 1996 Qian et al., , 1999 was obtained from Dr Mark Greene, University of Pennsylvania. The human EGF-receptor expression plasmid was a gift from Dr Gordon Gill, UCSD (San Diego, California, USA). Human herstatin cDNA was cloned as previously described (Doherty et al., 1999) .
Antibodies and growth factors
Rabbit polyclonal antibodies against the mouse FGF receptor-2, the human EGF-receptor, the human IGF-1 receptor b subunit, and the human HER-3 receptor were purchased from Santa Cruz Biotechnology Inc and were all used at a dilution of 1 : 1000. The anti-phosphotyrosine mouse monoclonal antibody (clone 4G10) was a gift from Dr Brian Druker, OHSU and was used at a concentration of 1 mg/ml. Rabbit polyclonal anti-neu(C) was made against a peptide identical to the last 15 residues of the carboxylterminus of the human p185HER-2 (Lin and Clinton, 1991) and was used at a 1 : 10 000 dilution. The anti-herstatin polyclonal antibody against the intron 8-encoded domain was prepared as described (Doherty et al., 1999) and was used at 1 : 10 000 dilution. The mouse monoclonal anti-herstatin antibody against the human intron 8-encoded domain was obtained from Upstate Biotechnology (Lake Placid, New York, USA) and was used at a concentration of 1 mg/ml. EGF and IGF-1 were purchased from Upstate Biotechnology and heregulin b1 was obtained from NeoMarkers (Fremont, CA, USA).
Cell culture
Cell lines were obtained from American Type Culture Collection (Rockville, MD, USA) unless speci®ed, and were maintained in DMEM supplemented with 10% fetal bovine serum and 0.05% gentamycin. The 17-3-1 cells are NIH3T3 cells stably transfected with a HER-2 cDNA expression vector (provided by Applied Biotechnology, Inc., Cambridge, MA, USA). All media and supplements were purchased from Gibco ± BRL (Life Technologies, Gaithersburg, MD, USA). For transient transfections, the cells were plated overnight to about 80% con¯uence and then were transfected with the expression plasmids indicated in the ®gure legends using either Lipofectamine (Gibco ± BRL) or Superfect (Qiagen) as per manufacturer's instructions.
Purification of herstatin and its intron 8-encoded peptide expressed in bacteria
The intron 8 cDNA and full-length human herstatin cDNA were cloned into the pET 30 bacterial expression vector (Invitrogen), expressed as polyhistidine tagged proteins, and puri®ed by nickel anity chromatography (Qiagen) as described (Doherty et al., 1999) .
Immunoprecipitation and Western blot analysis
Cells were washed twice with PBS and then lysed with MTG buer for immunoprecipitation (50 mM Tris pH 7.4, 100 mM NaCl, 1% nonidet-P40 (NP-40), 10% glycerol, 1 mM sodium orthovanadate (Na 3 VO 4 ), 1 mM phenylmethylsolfonyl¯uor-ide (PMSF). The extract was clari®ed by centrifugation and 1 mg of cell protein, quantitated by BioRad protein dye reagent, was incubated with the indicated antibody overnight with shaking at 48C, and with 50 ml of protein G Sepharose (BioRad) at 48C for 45 min. The immunecomplexes were washed three times by suspension in 500 ml of MTG buer, resolved by SDS ± PAGE, and analysed as a Western blot as previously described (Christianson et al., 1998) . For direct Western blot analysis, cells were extracted in mRIPA (50 mM Tris pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 0.1% deoxycholate, 1 mM orthovanadate, 1 mM PMSF), and 20 mg of protein were denatured in SDS-sample buer at 928C for 2 min. The proteins were then analysed as a Western blot (Christianson et al., 1998) . Equal loading of gels was con®rmed by Ponceau staining of cell proteins on the blots and by similar results obtained in replicate experiments.
Growth assay
Colony assays were performed by plating CHO cells at 2610 5 in six well plates overnight and transfecting with the indicated expression plasmids. At 48 hours after the addition of the DNA, the media were changed and the cells were treated with 0.6 mg/ml of G418 in complete growth media supplemented with 10% fetal bovine serum. The selection media were changed every 2 ± 3 days. At about 20 days, viable cells were quantitated using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), which assays mitochondrial viability (Hansen et al., 1989) , or were stained with crystal violet.
